title: Cutaneous side effects of new antitumor drugs: clinical features and management.
abstract: BACKGROUND
  Many new antitumor drugs have been approved in recent years. Their side-effect profiles are distinct from those of older drugs, and their adverse effects are sometimes highly specific, particularly with respect to the skin.
  
  
  METHODS
  This article is based on articles retrieved by a selective search in Medline and the database of the American Society of Clinical Oncology (ASCO), as well as on the authors' personal experience.
  
  
  RESULTS
  Cutaneous adverse effects are among the more common adverse effects of new antitumor drugs: they occur in up to 34% of patients receiving multikinase inhibitors, up to 90% of those receiving selective tyrosine kinase inhibitors (such as EGFR or mutant BRAF inhibitors), and up to 68% of those receiving immunotherapeutic agents (such as CTLA4 inhibitors). These adverse effects can be correlated with therapeutic benefit, but they can also be treatment-limiting because of their severity or visibility.
  
  
  CONCLUSIONS
  The recognition and proper management of cutaneous adverse effects is an important part of treatment with new antitumor drugs.
authors.affiliation: Department of Dermatology and Allergy, Hannover Skin Cancer Center, Hannover Medical School.
authors.forename: Ralf
authors.initials: R
authors.lastname: Gutzmer
authors.forename: Andreas
authors.initials: A
authors.lastname: Wollenberg
authors.forename: Selma
authors.initials: S
authors.lastname: Ugurel
authors.forename: Bernhard
authors.initials: B
authors.lastname: Homey
authors.forename: Arnold
authors.initials: A
authors.lastname: Ganser
authors.forename: Alexander
authors.initials: A
authors.lastname: Kapp
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D003430:Cross-Sectional Studies; D003875:Drug Eruptions / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D004791:Enzyme Inhibitors; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf